PIONIERKRAFT raises a high seven-figure amount in Series A financing round from climate tech investor First Imagine!

Share

Munich, 21 October 2024

Munich-based energy start-up PIONIERKRAFT has raised a high seven-figure amount in its Series A financing round, led by First Imagine!, a European venture capital firm focused on innovative solutions for a sustainable future. With this investment, PIONIERKRAFT will expand its energy-sharing solution for apartment buildings.

"When we founded PIONIERKRAFT in 2019, we saw an opportunity to build a foundation for the energy transition in small and medium-sized apartment buildings," says Andreas Eberhardt, CEO of PIONIERKRAFT. "This funding will help us scale our network of partners and ramp up mass production of our energy-sharing solution."

First Imagine! recognizes PIONIERKRAFT's growth potential and aims to accelerate the renewable energy transition. "Partnering with PIONIERKRAFT allows us to address the large sector of multi-tenant buildings in Germany that has been excluded from rooftop solar installations," says Alexander Starchenko, Managing Partner of First Imagine!.

The financing will also support the launch of PIONIERKRAFTwerk 3.0, setting new benchmarks in performance and ease of use, making the solution even more compelling to landlords and encouraging the decarbonization of Germany's apartment buildings.

PIONIERKRAFT has also welcomed Hartmut Michels, CEO of standata GmbH, to its advisory board. Michels' experience in the housing and energy sector will support the company’s growth and rollout of PIONIERKRAFTwerk. "The PIONIERKRAFTwerk is a big step towards the Home Energy Management System," Michels notes.

The Series A financing round was supported by Quantum Partners, an M&A consultancy based in Munich specializing in corporate finance and growth capital.

Contacts

PIONIERKRAFT GmbH
Agnes-Pockels-Bogen 1
80992 Munich
Daniela Schwendy
presse@pionierkraft.de
www.pionierkraft.de

Maisberger GmbH
Jennifer Appel/Julia Kirchhoff
Telefon: +49 (0)89 / 41 95 99-77, -55
E-Mail: pionierkraft@maisberger.com

Images

Andreas Eberhardt, CEO of PIONIERKRAFT
Andreas Eberhardt, CEO of PIONIERKRAFT
Download
Alexander Starchenko, managing partner of First Imagine!
Alexander Starchenko, managing partner of First Imagine!
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

eM Client Acquires Postbox Inc., Expanding Its Reach to a Broader User Base23.10.2024 11:08:58 CEST | Pressmeddelande

The acquisition solidifies eM Client’s position as a leading email client provider, bringing its innovative solutions to a growing audience. Prague, October 23, 2024 – eM Client, a leading provider of email client software, announced its acquisition of Postbox Inc., a well-established email application company based in the United States. This acquisition enables eM Client to extend its innovative solutions to an even larger global audience, reinforcing its position as one of the most comprehensive email platforms available. Summary: Who: eM Client has acquired Postbox Inc. What: The acquisition expands eM Client’s reach to a broader user base. When: October 22, 2024. Where: eM Client is based in Prague and serves a global customer base. Why: The acquisition strengthens eM Client’s leadership in the email client industry and brings its powerful tools to more users. eM Client has established itself as a top choice for email users, integrating email, calendars, contacts, tasks, and notes

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist22.10.2024 13:11:31 CEST | Pressmeddelande

Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025. “Grünenthal pioneered the research into NOP receptor agonists to deliver a unique and transformative first-in-class therapy option to millions of patients suffering from chronic pain,” says Gillian Burgess, Head of Research, Grünenthal. “With a unique mechanism of action for treating chronic pain, these molecules have the potential to deliver robust pain relief combined with an improved safety profile compared to the available standard of care.” Pre-clinical data show that NOP receptor agonists have the potential to act as pot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye